Central Venous Catheter (CVC)

Central Venous Catheter (CVC)

Clinical studies demonstrate ARROWg+ard antimicrobial technology’s ability to reduce catheter related blood stream infections1. It reduces bacterial colonisation of the catheter by 44 percent and catheter-related bacteremia by 79 percent2.

References:


1. Veenstra, D.L., Saint, S., Saha, S., Lumley, T., Sullivan, S.D. “Cost-Effectiveness of Antiseptic-Impregnated Central Venous Catheters for the Prevention of Catheter-Related Bloodstream Infection.” Journal of the American Medical Association, January 20, 1999, Vol. 281, Issue 3, pp. 261–267.
2. Maki, D.G., Stolz, S.M., Wheeler, S., Mermel, L.A. “Prevention of Central Venous Catheter-Related Bloodstream Infection With an Antiseptic-Impregnated Catheter: A Randomized, Controlled Trial.” Annals of Internal Medicine, August 15, 1997, Vol. 127, Issue 4, pp. 257–266.